Zobrazeno 1 - 10
of 763
pro vyhledávání: '"Michael H Davidson"'
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-9 (2024)
Abstract Background Elevated concentrations of low-density lipoprotein cholesterol (LDL-C) are linked to dementia risk, and conversely, increased plasma concentrations of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein-A1 (Apo-A1) ass
Externí odkaz:
https://doaj.org/article/ef79d49c09a54c3b8ca6b95c8c59316c
Autor:
Stephen J. Nicholls, Adam J. Nelson, John J. P. Kastelein, Marc Ditmarsch, Andrew Hsieh, Judith Johnson, Danielle Curcio, Douglas Kling, Carol F. Kirkpatrick, Michael H. Davidson
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 6, Pp n/a-n/a (2024)
Abstract Anacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor previously under development, exhibited an usually extended terminal half‐life and large food effect and accumulated in adipose tissue. Other CETP inhibitors have not shown
Externí odkaz:
https://doaj.org/article/6dc8b9af8eaf46bdbcd2ab961d9a1ab2
Autor:
Michael H. Davidson, MD
Publikováno v:
Journal of the Society for Cardiovascular Angiography & Interventions, Vol 3, Iss 10, Pp 102279- (2024)
Externí odkaz:
https://doaj.org/article/43b47a89eab447318e37f5658ca17580
Autor:
Bohdan B. Khomtchouk, Patrick Sun, Zane A. Maggio, Marc Ditmarsch, John J. P. Kastelein, Michael H. Davidson
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
IntroductionCholesteryl ester transfer protein (CETP) inhibitors, initially developed for treating hyperlipidemia, have shown promise in reducing the risk of new-onset diabetes during clinical trials. This positions CETP inhibitors as potential candi
Externí odkaz:
https://doaj.org/article/1eb16bfb01c4401cb43562904945fd68
Familial chylomicronemia syndrome (FCS) is an ultra-rare genetic disorder characterized by the abnormal build-up of chylomicrons, the largest type of lipoprotein, which transport dietary fat from the gut to the rest of the body. Patients with FCS oft
Publikováno v:
Heliyon, Vol 9, Iss 6, Pp e16913- (2023)
HempChoice® Hemp Oil Extract (Geocann, LLC) is an extract of the aerial parts of hemp (Cannabis sativa L.) primarily comprised of 55–75% cannabidiol (CBD), 1–15% other phytocannabinoids and 1–15% terpenes. The results of multiple safety studie
Externí odkaz:
https://doaj.org/article/c2f9ae99cec646bf8f96d5a87a790a3e
Publikováno v:
BMC Nephrology, Vol 23, Iss 1, Pp 1-11 (2022)
Abstract Background Cardiovascular disease is an important driver of the increased mortality associated with chronic kidney disease (CKD). Higher left ventricular mass (LVM) predicts increased risk of adverse cardiovascular outcomes and total mortali
Externí odkaz:
https://doaj.org/article/7729d432f28f4aa9b8b57cd0c25d0f0b
Autor:
Seth S Martin, Marc Ditmarsch, Mark Simmons, Nicholas Alp, Traci Turner, Michael H Davidson, John J P Kastelein
Publikováno v:
European heart journal. Cardiovascular pharmacotherapy, 9(2), 148-155. Oxford University Press
Background Low-density lipoprotein (LDL-C) lowering is imperative in cardiovascular disease prevention. Effectively translating the evidence for LDL-C lowering to maximize clinical and public health benefits depends on the availability of accurate LD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67bb37bfb9ceff37bc28dc1096578ba1
https://doi.org/10.1093/ehjcvp/pvac056
https://doi.org/10.1093/ehjcvp/pvac056
Autor:
Matthew R. Deshotels, Trevor D. Hadley, Mendel Roth, Ali M. Agha, Vishnu Priya Pulipati, Anne K. Nugent, Salim S. Virani, Vijay Nambi, Patrick M. Moriarty, Michael H. Davidson, Christie M. Ballantyne
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 42:1461-1467
Background: Severe hypertriglyceridemia is often caused by variants in genes of triglyceride metabolism. These variants include rare, heterozygous pathogenic variants (PVs), or multiple common, small-effect single nucleotide polymorphisms that can be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15f33581170536285b3ec82b2623c1c5
https://doi.org/10.1161/atvbaha.122.318445
https://doi.org/10.1161/atvbaha.122.318445
Autor:
Stephen J. Nicholls, Marc Ditmarsch, John J. Kastelein, Scott P. Rigby, Douglas Kling, Danielle L. Curcio, Nicholas John Alp, Michael H. Davidson
Publikováno v:
Nature medicine, 28(8), 1672-1678. Nature Publishing Group
Global guidelines for the management of high-cardiovascular-risk patients include aggressive goals for low-density lipoprotein cholesterol (LDL-C). Statin therapy alone is often insufficient to reach goals and nonstatin options have limitations. Here
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5885fc425a51c1d1e0eb56e44c83b5f0
http://www.scopus.com/inward/record.url?scp=85135835966&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85135835966&partnerID=8YFLogxK